Yep !! the Annual Report and the June quarterly will demonstrate the revenue (cash receipts) growth from the NG Biotech orders. I do believe that a significant problem that plagues the share price is that there hasn't been a revenue update. last revenue figures are for half year ending 31st December 2019. It is currently May and the market has not been notified of the revenue earned during the March quarterly and April. It will just be a matter of patience.
Potential SP Valuation of AT1 - 80 cents to 1.30/share, page-331
-
- There are more pages in this discussion • 1,058 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
